Dabigatran for Japanese Patients with Atrial Fibrillation and Prior Stroke: A Subgroup Analysis of the J-Dabigatran Surveillance Program

Yasaka, Masahiro; Uchiyama, Shinichiro; Atarashi, Hirotsugu; Okumura, Ken; Koretsune, Yukihiro; Yamashita, Takeshi; Taniguchi, Atsuhiko; Fukaya, Taku; Inoue, Hiroshi; Investigators, J-Dabigatran Surveillance

doi:10.1016/j.jstrokecerebrovasdis.2020.104717

Cited by 3 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to dabigatran, other DOACs (rivaroxaban, apixaban, and edoxaban) are now in clinical use and experience with these drugs has accrued to provide information on drug characteristics and their use in different patient populations [14]. For example, there may be a preference to use dabigatran in patients undergoing catheter ablation, as mentioned above [16], and in those with and without previous stroke/transient ischemic attack support, particularly for secondary prevention due to the low incidence of intracranial bleeding [18].…”

Section: Discussionmentioning

confidence: 99%

Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2

Yamashita

Uchiyama

Atarashi

et al. 2022

Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2

Yamashita

Uchiyama

Atarashi

et al. 2022

Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

“…48 A non-interventional prospective study in the Japanese AF population showed that the risks of both thrombotic and bleeding events were numerically lower in patients treated with dabigatran 150 mg twice daily compared with dabigatran 110 mg twice daily. 49 In the absence of randomised head-to-head studies comparing NOACs, the selection of medications should be based on individual patient characteristics. It is challenging to recommend a single drug for the entire population.…”

Section: Primary Stroke Preventionmentioning

confidence: 99%

“…[ 48 ] A non-interventional prospective study in the Japanese AF population showed that the risks of both thrombotic and bleeding events were numerically lower in patients treated with dabigatran 150 mg twice daily compared with dabigatran 110 mg twice daily. [ 49 ]…”

Section: Primary Stroke Preventionmentioning

confidence: 99%

Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 1

Ho,

Ton,

Nguyen

et al. 2023

Eur Cardiol

View full text Add to dashboard Cite

In Asia, especially Vietnam, AF is a common arrhythmia and is linked to a higher risk of stroke and systemic embolism. Anticoagulation therapy for stroke prevention in AF patients can result in bleeding complications. To effectively manage AF, adopting appropriate anticoagulation and addressing modifiable risk factors are crucial. Vietnamese clinicians are particularly interested in non-vitamin K antagonist oral anticoagulants (NOACs), a recent development in AF treatment. However, the lack of head-to-head trials comparing NOACs makes selecting a specific NOAC challenging. This review aims to provide a comprehensive overview of the available clinical evidence on NOACs for stroke prevention in AF to assist clinicians in making informed decisions and improving treatment outcomes in patients with AF. The first part of this review will present the current landscape of AF in Vietnam, focusing on AF prevalence and highlighting gaps in clinical practice. Furthermore, this part extensively discusses the anticoagulation strategy for both primary and secondary stroke prevention in AF.

show abstract

“…The cerebral stroke is in 85% of cases of the ischemic type and in 15% of cases of the hemorrhagic type, in this case affecting younger subjects (usually hypertensive or carriers of vascular malformation) [ 3 ]. Stroke remains the second cause of mortality and the first of disability [ 3 , 4 , 5 ]. In 2019, the Italian National Health Service reported that there were 20,000 cases of stroke in Italy, 80% of which were first episodes, while 20% were recurrences [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

A System for Neuromotor Based Rehabilitation on a Passive Robotic Aid

Righi

Magrini

Dolciotti

et al. 2021

Sensors

View full text Add to dashboard Cite

In the aging world population, the occurrence of neuromotor deficits arising from stroke and other medical conditions is expected to grow, demanding the design of new and more effective approaches to rehabilitation. In this paper, we show how the combination of robotic technologies with progress in exergaming methodologies may lead to the creation of new rehabilitation protocols favoring motor re-learning. To this end, we introduce the Track-Hold system for neuromotor rehabilitation based on a passive robotic arm and integrated software. A special configuration of weights on the robotic arm fully balances the weight of the patients’ arm, allowing them to perform a purely neurological task, overcoming the muscular effort of similar free-hand exercises. A set of adaptive and configurable exercises are proposed to patients through a large display and a graphical user interface. Common everyday tasks are also proposed for patients to learn again the associated actions in a persistent way, thus improving life independence. A data analysis module was also designed to monitor progress and compute indices of post-stroke neurological damage and Parkinsonian-type disorders. The system was tested in the lab and in a pilot project involving five patients in the post-stroke chronic stage with partial paralysis of the right upper limb, showing encouraging preliminary results.

show abstract

Dabigatran for Japanese Patients with Atrial Fibrillation and Prior Stroke: A Subgroup Analysis of the J-Dabigatran Surveillance Program

Cited by 3 publications

References 31 publications

Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2

Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2

Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 1

A System for Neuromotor Based Rehabilitation on a Passive Robotic Aid

Contact Info

Product

Resources

About